Active Clinical Trials

If you would like to be considered for one of the clinical trials listed below please contact our Clinical Research Team at:

DukeDermatologyClinicalResearch@duke.edu
Phone: 919-684-8132

Learn More about Our Clinical Trials

Active Clinical Trials

Gorlin Syndrome

  • Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome.
    • Status: Open, not enrolling at this time
    • PI: Dr. Meenal Kheterpal
    • More Details

 

Advanced Skin Cancers

  • A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients with Advanced Cutaneous Malignancies.
    • Status: Enrolling participants.
    • PI: Dr. Meenal Kheterpal                        
    • More Details

 

Hidradenitis Suppurativa (HS)

  • Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository- HS PROGRESS
  • Biorepository of Patients with Hidradenitis Suppurativa (HS): Determination of potential predictors and moderators of treatment response in patients with HS.
  • A Study to Test the Long-term Treatment of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT).
  • A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS).
  • A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.


Cutaneous Sarcoidosis

  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Lupus

  • A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/​or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/​or Intolerant to Antimalarial Therapy (AMETHYST).
  • A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)
  • A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations